3 British AI Healthcare Stocks With Revenue Growth Up To 16%

Option traders preparing for a spike in volatility as AI related stocks swing more sharply have put artificial intelligence in the spotlight for UK investors. Rapid shifts in sentiment can punish crowded trades and leave quieter sectors overlooked. Healthcare AI sits in that overlooked camp. In this article you will see three transforming AI healthcare stocks from the screener that bring this theme into clear, concrete focus.

The three AI healthcare stocks highlighted next are only a starting sample, and the full screen surfaced 5 more companies with equally compelling narratives that are not covered here. To see the wider opportunity set and quickly pinpoint which tickers best fit your own thesis, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Haleon (LSE:HLN)

Overview: Haleon is a global consumer healthcare group using its Microsoft-backed AI and data partnership to sharpen product development, marketing and supply decisions across oral health, pain relief, respiratory and nutrition brands.

Operations: Haleon generates £3.8b in North America, £4.7b across Europe, the Middle East, Africa and Latin America, and £2.6b in Asia Pacific.

Market Cap: £33.0b

Haleon matters for this AI healthcare screen because its everyday products sit where data, digital behaviour and health decisions meet. This gives its partnership with Microsoft real room to influence how consumers choose and use treatment options.

"Extending the current productivity and AI programme, which has already delivered 140 basis points of gross margin improvement alongside SKU and formulation reduction, provides room for further structural cost savings that could widen net margins and raise free cash flow beyond what is implied by modest top line growth."

The big swing factor is whether one quiet shift in how this AI programme feeds into pricing and mix truly moves group profitability.

If that margin shift is the real hinge, read the full narrative for Haleon to see how Haleon’s AI rollout could accelerate or stall that profit story.

Abingdon Health (AIM:ABDX)

Overview: Abingdon Health develops and manufactures rapid lateral flow diagnostic tests and services, anchored by its AppDx smartphone reader and wider AI enabled digital health tools.

Operations: Abingdon Health generates £5.0 million from Contract Development, £4.1 million from Regulatory work, £1.3 million from Contract Manufacturing and £0.6 million from Product Sales, serving customers across Europe, the USA and Canada, the UK and other regions.

Market Cap: £39.2 million

Abingdon Health matters for this AI healthcare screen because it links physical test strips to software driven interpretation, which is exactly where diagnostics shift from simple yes or no answers to rich, decision ready data.

"Growing use of digital tools in diagnostics, including smartphone based test readers, aligns with Abingdon’s AppDx platform, which can turn standard lateral flow tests into quantifiable, software linked products and may support higher value contracts and improved gross margins."

The real swing factor is how one unresolved pressure on its economics interacts with that digital testing push and shapes future profitability.

That pressure point is exactly what full narrative for Abingdon Health unpacks, mapping how Abingdon Health’s AI tools could turn contracting work into scalable, higher margin diagnostics momentum.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca develops and sells prescription medicines across oncology, cardiovascular, respiratory, vaccines and rare diseases, increasingly weaving AI into R&D.

Operations: The business generates its $61.4b in revenue from pharmaceuticals, with performance anchored in its global prescription medicines portfolio.

Market Cap: £193.0b

AstraZeneca matters in this AI healthcare screen because its cancer research teams are wiring artificial intelligence directly into how future drugs are discovered, trialled and tailored. That shift in how evidence is generated is where the potential economic impact starts to get interesting.

"Ongoing investments in transformative technologies (such as next-generation ADCs, bispecific antibodies, mRNA platforms, and AI/digital-enabled clinical trial efficiencies) are expected to accelerate drug development cycles, enable precision medicine launches, and support higher net margins due to more efficient R&D and premium pricing potential."

What happens when that AI driven trial engine meets one quietly changing assumption about how much margin headroom future oncology launches really have?

That margin question sits at the heart of the full narrative for AstraZeneca, which shows where AstraZeneca’s AI engine could accelerate returns and where risks quietly build.

Seeking Fresh Alternatives Beyond Healthcare AI

Fresh opportunities can move fast. Breakout themes, early momentum and under the radar for now stories can change once the crowd piles in. Scan the next wave before it drops and consider acting while ideas are still developing.

• Target steady income streams as income seekers sift through the 2 dividend fortresses built to spotlight payouts that could help keep portfolios supported while rates shift.
• Track potential infrastructure-related opportunities by running through the 42 power grid technology and infrastructure stocks where companies connected to grid upgrades and electrification are grouped before any potential changes are fully reflected in the market.
• Prepare for possible shifts in materials demand using the curated 32 best rare earth metal stocks focused on producers that could become more relevant if demand momentum builds.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com